Hair Relaxer Lawsuit 2026: MDL 3060, Uterine Cancer & Bellwether Update
Hair relaxer lawsuit claims allege that certain chemical hair straightener and relaxer products contributed to reproductive cancers and that manufacturers failed to adequately warn consumers about alleged risks. Federal cases are centralized in MDL 3060 in the Northern District of Illinois before Judge Mary M. Rowland, and defendants dispute liability and individualized causation.
Choose the Hair Relaxer Lawsuit Information You Need
Start with potential eligibility or current MDL status, then move to the medical research, settlement factors, calculator or documentation checklist.
What the Hair Relaxer Lawsuit Alleges
Federal hair relaxer lawsuits allege that manufacturers marketed and sold chemical hair straightening products that exposed users to substances capable of endocrine disruption or other harmful effects and that warnings were inadequate. The centralized litigation includes claims involving multiple manufacturers, brands and formulations, so product identification and exposure history remain important case-specific issues.
Failure to Warn
Plaintiffs allege that consumers were not adequately warned about claimed long-term health risks associated with repeated use of certain relaxer products.
Reproductive Cancers
The court's bellwether order identifies uterine, endometrial and ovarian cancer as designated injuries for the reproductive-cancer bellwether pool.
Liability Is Disputed
Defendants may contest general causation, specific causation, product identification, warning theories, timing, damages and other elements of individual claims.
Who May Qualify for a Hair Relaxer Lawsuit?
There is no single public rule that automatically determines legal eligibility. A review generally considers the exact products used, duration and frequency of use, diagnosis, treatment, timing, medical history, applicable state law and the evidence connecting the claimed injury to a defendant's product.
Product Use Evidence
- Brand or product names, packaging, photos, purchase records or salon history.
- Approximate years of use and frequency of application.
- Whether multiple relaxer or straightener products were used over time.
Diagnosis Evidence
- Uterine or endometrial cancer.
- Ovarian cancer.
- Other claimed injuries require case-specific review and may not be part of the bellwether-designated reproductive-cancer pool.
Treatment & Damages
Surgery, hysterectomy, chemotherapy, radiation, fertility impact, permanent impairment, medical expenses, wage loss and future care may affect claimed damages.
Timing & Alternative Risk Factors
Attorneys and experts may evaluate age, family history, reproductive history, other exposures, medical conditions and the timing between product use and diagnosis.
Hair Relaxer MDL 3060 Status in August 2026
Federal hair relaxer cases are centralized in the Northern District of Illinois before Judge Mary M. Rowland as MDL No. 3060. JPML's August 3, 2026 report lists 11,779 pending actions and 16,199 historical actions.
February 6, 2023 — MDL 3060 Centralized
Federal hair relaxer marketing, sales-practices and products-liability cases were transferred to the Northern District of Illinois for coordinated pretrial proceedings.
January 31, 2025 — Bellwether Procedure Order
The court adopted a bellwether selection process and expanded the initial discovery pool to improve the chance of trying representative cases.
2025–2026 — General & Case-Specific Expert Work
The court's schedule calls for general-causation and case-specific expert disclosures, discovery and Rule 702/Daubert motion practice before bellwether trials.
August 3, 2026 — 11,779 Actions Pending
JPML listed 11,779 pending actions and 16,199 historical actions in MDL 3060.
October 16, 2026 — Expert Discovery Deadline
The published bellwether schedule sets this date for the close of case-specific and other non-general-causation expert discovery.
November 2026–January 2027 — Dispositive / Daubert Briefing
The schedule lists November 16 for summary judgment and nongeneral-causation Daubert motions, December 16 for responses and January 6, 2027 for replies.
What Research Says About Hair Straighteners and Reproductive Cancer
The National Institute of Environmental Health Sciences' Sister Study reported that women who frequently used hair straightening products—defined as more than four times in the prior year—had a higher rate of uterine cancer than women who reported no use. The 2022 study reported a hazard ratio of 2.55 for frequent use versus never use. Researchers estimated uterine cancer risk by age 70 at 1.64% for non-users and 4.05% for frequent users.
A separate 2021 Sister Study analysis reported that frequent use of straighteners, relaxers or pressing products was associated with increased ovarian cancer incidence, with a reported hazard ratio of 2.19. Both studies were observational and do not prove that a particular product caused an individual's cancer.
Frequent Use Association
The 2022 study found a stronger association among participants reporting straightener use more than four times in the prior year.
2021 Sister Study
Frequent straightener/relaxer or pressing-product use was associated with higher ovarian cancer incidence in the cohort.
Association ≠ Individual Proof
Epidemiologic associations are important scientific evidence, but individual legal and medical causation require additional evidence.
Uterine, Endometrial and Ovarian Cancer Claims
The federal bellwether order identifies uterine, endometrial and ovarian cancer as designated reproductive-cancer injuries for bellwether selection. Those categories matter procedurally because the bellwether program is intended to test representative claims, but an individual's legal case still depends on diagnosis, product use, causation evidence, defendants and applicable law.
Uterine Cancer
Medical records may include pathology, staging, hysterectomy, oncology treatment, recurrence information and follow-up care.
Endometrial Cancer
Endometrial cancer arises from the uterine lining. Diagnosis type, stage, treatment and prognosis can materially affect claimed damages.
Ovarian Cancer
Pathology, surgery, chemotherapy, recurrence, fertility impact and long-term treatment can be important evidence.
Hair Relaxer Products and Defendants Identified in MDL Materials
The court's Short Form Complaint includes numerous products and manufacturers. Product identity should be verified from packaging, photos, receipts, salon records, purchase history or other evidence rather than assumed from the general category of “hair relaxer.” The examples below are not exhaustive.
| Company / Group | Example Products or Brands | Why Identification Matters |
|---|---|---|
| L'Oréal / SoftSheen-Carson | Dark & Lovely, Optimum, Mizani and other listed products | The exact product, formulation and use period can affect defendant and exposure analysis. |
| Revlon-related entities | Products identified in individual complaints and MDL materials | Corporate entity and product proof are case-specific. |
| Strength of Nature / Godrej | Motions, Just for Me and other listed relaxer products | Long-term users may have used several products over different periods. |
| Namaste / Dabur | ORS Olive Oil relaxer and texturizer products listed in MDL forms | Packaging, salon records and purchase history can help establish exposure. |
| Luster Products | Pink Oil Moisturizer and PCJ relaxer products listed in MDL forms | Precise product identification helps connect a claimant to the appropriate defendant. |
What the FDA Says About Hair Relaxers and Formaldehyde-Releasing Smoothing Products
The FDA regulates cosmetics, including hair relaxers and smoothing products, but cosmetic products generally are not pre-approved by the agency before sale. FDA advises consumers to follow directions for relaxers and to report bad reactions.
FDA separately warns that many hair smoothing or straightening products release formaldehyde gas when heated. Formaldehyde exposure can irritate the eyes, nose, lungs and skin, and formaldehyde is classified as a human carcinogen. That FDA information is important safety context, but it should not be treated as proof that every relaxer product in MDL 3060 contains formaldehyde or that formaldehyde caused an individual's reproductive cancer.
Evidence That May Matter in a Hair Relaxer Lawsuit
Product Proof
Packaging, photos, receipts, loyalty records, salon records, statements from stylists or family members and long-term purchase history.
Diagnosis Records
Pathology, imaging, operative reports, oncology records, staging information and treatment records.
Exposure Timeline
Approximate age when use began, years of use, frequency, brands and whether product use continued before diagnosis.
Damages Records
Medical bills, wage loss, fertility impact, future care, disability evidence and other documented economic or personal losses.
Hair Relaxer Lawsuit Settlement Status and Value Factors
No publicly announced global settlement program or universal payout matrix for MDL 3060 was identified in the primary litigation sources reviewed for this update. Published dollar ranges should therefore be treated as editorial estimates or planning tools—not official averages, court-approved tiers, settlement offers or guaranteed compensation.
Cancer Type & Stage
Diagnosis, stage, recurrence, prognosis and permanency can materially affect damages.
Treatment Burden
Hysterectomy, other surgery, chemotherapy, radiation and continuing oncology care may affect claimed losses.
Fertility Impact
Loss of fertility, early menopause and reproductive consequences may be significant in some cases.
Product Identification
Reliable evidence tying a claimant to a specific defendant's product can affect liability and settlement leverage.
Causation Evidence
Expert rulings, scientific evidence, exposure history and alternative risk factors can influence case viability.
Economic Loss
Medical expenses, lost wages, reduced earning capacity and future care may be relevant where recoverable.
How a Hair Relaxer Cancer Claim May Be Evaluated
Identify Products
List brands, formulations, approximate years of use and frequency.
Document Diagnosis
Collect pathology, staging, surgery, oncology and treatment records.
Build the Timeline
Compare product use with diagnosis, symptoms, treatment and other risk factors.
Review Causation
Assess scientific evidence, alternative causes and defendant-specific proof.
Check Filing Rules
Review state statutes, discovery rules, venue and any MDL requirements.
Preserve Damages Proof
Keep bills, wage records, fertility-related records and future-care evidence.
Hair Relaxer Lawsuit Statute of Limitations
There is no single nationwide filing deadline for every hair relaxer claim. Product-liability statutes of limitation and statutes of repose vary by state, and the start date can depend on diagnosis, discovery of a potential connection, product use, defendant, residence, purchase location and other facts.
Hair Relaxer Lawsuit FAQ
How many hair relaxer lawsuits are pending?
JPML's August 3, 2026 report lists 11,779 actions pending in MDL 3060 and 16,199 historical actions.
Is the hair relaxer litigation a class action?
The federal cases are coordinated in multidistrict litigation, or MDL 3060. Individual plaintiffs generally retain individual claims, causation issues and damages rather than receiving one automatic class-wide payment.
Which cancers are central to the bellwether process?
The court's bellwether order identifies uterine, endometrial and ovarian cancer as designated reproductive-cancer injuries for the bellwether pool.
Did the NIH study find a 2.5-times higher uterine cancer risk?
The 2022 Sister Study reported a hazard ratio of 2.55 for women reporting frequent straightener use—more than four times in the prior year—compared with never users. That is an observational association, not proof of individual causation.
Has there been a global hair relaxer settlement?
No public universal MDL 3060 settlement matrix or global payout program was identified in the primary sources reviewed for this August 2026 update.
Do all hair relaxers contain formaldehyde?
No. FDA's formaldehyde guidance specifically discusses many hair smoothing or straightening products that release formaldehyde when heated. Product formulations differ, so the exact product and ingredient evidence should be verified rather than assumed.
What evidence can help prove long-term hair relaxer use?
Packaging, photos, receipts, salon records, store loyalty histories, testimony from stylists or family members and consistent personal-use history may help establish product exposure.
What is the next major phase of MDL 3060?
The published bellwether schedule calls for case-specific expert discovery to close October 16, 2026, followed by summary judgment and nongeneral-causation Daubert briefing beginning November 16.
Hair Relaxer Lawsuit Sources and Official References
- Judicial Panel on Multidistrict Litigation — Pending MDL Reports. August 3, 2026 report lists 11,779 pending and 16,199 historical actions in MDL 3060.
- U.S. District Court for the Northern District of Illinois — MDL information. Official court source for MDL 3060.
- January 31, 2025 Bellwether Selection Schedule and Procedures. Court order describing designated reproductive-cancer injuries and the 2025–2027 bellwether/expert schedule.
- MDL 3060 Short Form Complaint. Identifies defendants and hair relaxer products used for individual complaints.
- NIEHS Sister Study — hair straighteners and uterine/ovarian cancer research. Summarizes the cohort findings and links the underlying research.
- White AJ, et al. Use of hair products in relation to ovarian cancer risk. Carcinogenesis, 2021.
- FDA — Hair Dye and Hair Relaxers. Consumer safety and adverse-reaction guidance.
- FDA — Hair Smoothing Products That Release Formaldehyde When Heated. Formaldehyde safety and regulatory context.
Request a Confidential Hair Relaxer Case Review
If you used chemical hair relaxers or straighteners and were later diagnosed with a serious reproductive cancer, submit the product, diagnosis, treatment and timing information you know now for review.
